Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26290
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLiu, Howard Yu-Hao-
dc.contributor.authorLee, Yoo-Young Dominique-
dc.contributor.authorSridharan, Swetha-
dc.contributor.authorChoong, Ee Siang-
dc.contributor.authorLe, Hien-
dc.contributor.authorWang, Wei-
dc.contributor.authorKhor, Richard-
dc.contributor.authorChu, Julie-
dc.contributor.authorOar, Andrew-
dc.contributor.authorMott, Rebekah-
dc.contributor.authorSmart, Joanne-
dc.contributor.authorJenkins, Trish-
dc.contributor.authorAnderson, Nigel-
dc.contributor.authorCross, Shamira-
dc.contributor.authorLoo, Kee Fong-
dc.contributor.authorWigg, Alan-
dc.contributor.authorStuart, Katherine-
dc.contributor.authorPryor, David-
dc.date2021-04-22-
dc.date.accessioned2021-04-26T22:38:32Z-
dc.date.available2021-04-26T22:38:32Z-
dc.date.issued2021-04-22-
dc.identifier.citationJournal of Medical Imaging and Radiation Oncology 2021; online first: 22 Aprilen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26290-
dc.description.abstractStereotactic body radiotherapy (SBRT) is an emerging, therapeutic option in the management of hepatocellular carcinoma (HCC). A multicentre Liver Ablative Stereotactic Radiation (LASR) database was established to provide a collaborative platform for Australian institutions to define the practice of liver SBRT for HCC. This study explores the patterns of SBRT practice amongst Australian institutions. This was a multi-institutional retrospective study of patients treated with SBRT for HCC at 10 institutions between January 2013 and December 2019. Patients' demographics, disease characteristics and SBRT details were evaluated. Three hundred and seventeen patients were evaluated with a median age of 67 years (range, 32-90). Liver cirrhosis was present in 88.6%, baseline Child-Pugh score was A5/6 in 85.1% and B7/8 in 13.2%. Median size of HCC treated was 30 mm (range, 10-280). 63.1% had early-stage disease (Barcelona clinic liver cancer (BCLC) stage 0/A) and 36% had intermediate/advanced-stage disease (BCLC B/C). In 2013/2014, six courses of SBRT were delivered, increasing to 108 in 2019. SBRT was prescribed in five fractions for 71.3% of the cohort. The most common dose fractionation schedule was 40 Gy in five fractions (24.3%). Median biologically effective dose (BED10 ) delivered was 85.5 Gy for early-stage and 60 Gy for intermediate/advanced disease, respectively. The most common prescription range was 100-120 Gy BED10 (32.8%). SBRT utilisation for HCC is increasing in Australia. There was wide variation in size of tumours and disease stages treated, and prescription patterns. Uniform reporting of clinical and dosimetric details are important in refining the role of liver SBRT.en
dc.language.isoeng
dc.subjectdose fractionationen
dc.subjecthepatocellular carcinomaen
dc.subjectpractice patternsen
dc.subjectstereotactic ablative radiotherapyen
dc.subjectstereotactic body radiotherapyen
dc.titleStereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Medical Imaging and Radiation Oncologyen
dc.identifier.affiliationDepartment of Radiation Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.affiliationDepartment of Radiation Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australiaen
dc.identifier.affiliationIcon Cancer Centre, Gold Coast University Hospital, Gold Coast, Queensland, Australiaen
dc.identifier.affiliationDepartment of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australiaen
dc.identifier.affiliationDepartment of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australiaen
dc.identifier.affiliationFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australiaen
dc.identifier.affiliationDepartment of Radiation Oncology, The Crown Princess Mary Cancer Centre, Sydney, New South Wales, Australiaen
dc.identifier.affiliationDepartment of Radiation Oncology, Nepean Cancer Care Centre, Sydney, New South Wales, Australiaen
dc.identifier.affiliationIcon Cancer Centre, Greenslopes Hospital, Brisbane, Queensland, Australiaen
dc.identifier.affiliationDepartment of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Queensland, Australiaen
dc.identifier.affiliationHepatology and Liver Transplantation Medicine Unit, Flinders Medical Centre, Adelaide, South Australia, Australiaen
dc.identifier.affiliationDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationRadiation Oncologyen
dc.identifier.doi10.1111/1754-9485.13184en
dc.type.contentTexten
dc.identifier.orcid0000-0002-9902-9529en
dc.identifier.orcid0000-0003-2574-2476en
dc.identifier.pubmedid33890425
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Sep 22, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.